TACSTD2 and cancer: In the field of oncology, currently approved ADCs target specific proteins overexpressed by cancer cells, such as HER2, trophoblast cell surface antigen 2 (Trop2), Nectin‐4, and EGFR in solid tumors, and CD19, CD22, CD33, CD30, and CD79b in hematologic malignancies.85